We recently published 10 Stocks Stealing Today’s Spotlight; 5 on All-Time Highs. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best performers on Wednesday. Hims & Hers soared by 16.18 percent on ...

Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage with an Overweight rating and a $35 price target, framing the telehealth ...

Hims is expanding beyond telehealth with a push into hormone care, while building out at-home testing and virtual care services. ・Peptides is also seen as the next growth driver, with Bank of America ...

The next-generation healthcare services specialist has launched offerings in a new segment. This is laser-focused on female health. Wednesday morning, Hims & Hers announced it was launching a new ...

Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is ...

Hims & Hers Health stock beat on earnings but suffered a steep sales slowdown in Q4. Hims & Hers is trying to figure out how to grow without selling GLP-1 drugs. Hims & Hers reported its earnings for ...

Hims & Hers Health shares are down 30%, but I maintain a Buy rating due to compelling long-term growth levers. HIMS's core business growth is slowing, yet margin expansion, product innovation, and ...

Hims & Hers Health (HIMS) on Wednesday announced that women experiencing perimenopause and menopause can secure a reliable supply of estrogen patches through its platform as demand for the hormone ...